Akeso, Inc. (HK:9926) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Akeso, Inc. has announced the approval of its non-oncology drug, ebronucimab (PCSK9), by China’s National Medical Products Administration for treating hypercholesterolemia and familial hypercholesterolaemia. This marks the company’s fifth commercial product and is expected to meet the high market demand for metabolic disease treatments in China, potentially reducing cardiovascular event risks. The company is optimistic about ebronucimab’s role in strengthening its long-term global development through a targeted commercialization strategy.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.